Antibody-Drug Conjugates The 21st Century Magic Bullets for Cancer /
The field of antibody-drug conjugates (ADCs) has undergone remarkable advancements in recent years, marked by significant progress in both drug approvals and ongoing clinical development. Since the approval of the first ADC in 2010 (gemtuzumab ozogamicin, Mylotarg®), the landscape has expanded drama...
שמור ב:
| מחבר תאגידי: | |
|---|---|
| מחברים אחרים: | , |
| פורמט: | אלקטרוני ספר אלקטרוני |
| שפה: | אנגלית |
| יצא לאור: |
Cham :
Springer Nature Switzerland : Imprint: Springer,
2025.
|
| מהדורה: | 2nd ed. 2025. |
| סדרה: | AAPS Advances in the Pharmaceutical Sciences Series,
17 |
| נושאים: | |
| גישה מקוונת: | https://doi.org/10.1007/978-3-031-83005-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
System Under Maintenance
Our Library Management System is currently under maintenance.
Holdings and item availability information is currently unavailable. Please accept our apologies for any inconvenience this may cause and contact us for further assistance: